Home›Companies›Biotech & Pharma›FluidForm Bio

FluidForm Bio, Inc.

Develops cell therapies using printed human tissue for people with chronic diseases.

Updated Nov 9, 2026·Latest SEC filing Aug 27, 2026·Suggest an edit

About FluidForm Bio

FluidForm Bio is a private company based in Waltham, Massachusetts. It has reported $1,703,371 raised in one offering on Form D since August 2026. Its chief executive is Michael Graffeo.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Jul 16, 2026Aug 27, 2026$1,703,371of $3.0M target20$85,169Equity, OptionsRule 506(b)Form D ↗

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on FluidForm Bio's Form D filed Aug 27, 2026.

Adam Feinberg
Adam Feinberg
Chief Technology Officer & Co-founder, director
Michael Graffeo
Michael Graffeo
Chief Executive Officer & Co-founder, director
EW
Erik Waters
Chief Financial Officer

Sources

  1. SECFluidForm Bio, Inc. filing history
  2. CompanyFluidForm Bio about
  3. CompanyCHIPS announcement